PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Cenciarelli, Carlo ^a   Marei, Hany E S ^b   Zonfrillo, Manuela ^a   Pierimarchi, Pasquale ^a   Paldino, Emanuela ^c   Casalbore, Patrizia ^c   Felsani, Armando ^c   Vescovi, Angelo Luigi ^d   Maira, Giulio ^e   Mangiola, Annunziato ^e  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b Mansoura University   (Egypt)

^c Institute of Cell Biology and Neurobiology   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CRENOLANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; NOTCH1 RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN;

ADULT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MTS ASSAY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL CYCLE; DRUG EFFECTS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84920800655     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-247     Document Type: Article

References (50)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 1, 15:1311-1333. 10.1101/gad.891601
2. Aster JC, Blacklow SC: Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 2012,30(19):2418-2420. 10.1200/JCO.2012.42.0992
3. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L: Targeting Notch to target cancer stem cells. Clin Cancer Res 2010,16(12):3141-3152. Review 10.1158/1078-0432.CCR-09-2823
4. Takebe N, Nguyen D, Yang SX: Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014,141(2):140-149. 10.1016/j.pharmthera.2013.09.005
5. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA: Expression of Notch-1 and its ligands, delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005,65(6):2353-2363. 10.1158/0008-5472.CAN-04-1890
6. Dufraine J, Funahashi Y, Kitajewski J: Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008,27(38):5132-5137. 10.1038/onc.2008.227
7. Fortini ME: Gamma-secretase-mediated proteolysis in cell-surface-receptor signaling. Nat Rev Mol Cell Biol 2002,2(9):673-684.
8. Ronchini C, Capobianco AJ: Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001,21(17):5925-5934. 10.1128/MCB.21.17.5925-5934.2001
9. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, Ferrando AA, Levin SD, Geng Y, Von Boehmer H, Sicinki P: Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003,4(6):451-461. 10.1016/S1535-6108(03)00301-5
10. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, Pear WS, Aster JC: c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 1, 20:2096-2109. 10.1101/gad.1450406
11. Chen Y, Fischer WH, Gill GN: Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. J Biol Chem 1997,272(22):14110-14114. 10.1074/jbc.272.22.14110
12. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E: Glioblastoma subclasses can be defined by activity among signal transduction pathway and associated genomic alterations. PLoS One 2009,4(11):e7752. 10.1371/journal.pone.0007752
13. Le Mercier M, Hastir D, Moles Lopez X, De Neve N, Maris C, Trepant AL, Rorive S, Decaestecker C, Salmon I: A simplified approach for the molecular classification of Glioblastomas. PLoS One 2012,7(9):e45475. 10.1371/journal.pone.0045475
14. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat 1, 32:74-89. 10.1016/j.ctrv.2006.01.003
15. Gan HK, Kaye AH, Luwor RB: The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 1, 16:748-754. 10.1016/j.jocn.2008.12.005
16. Collaborators (231): The Cancer Genome Atlas project. Comprehensive genomic characterization defines human glioblastoma genes and core pathway. Nature 1, 455:1061-1068. 10.1038/nature07385
17. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1, 91:7727-7731. 10.1073/pnas.91.16.7727
18. Dai C, Celestino JC, Okada Y, Luois DN, Fuller GN, Holland EC: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 1, 15:1913-1925. 10.1101/gad.903001
19. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P: Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 1, 26:6781-6790. 10.1523/JNEUROSCI.0514-06.2006
20. Fredriksson L, Li H, Eriksson U: The PDGF family: four gene products forms five dimeric isoforms. Cytokine Growth Factor Rev 1, 15:197-204. 10.1016/j.cytogfr.2004.03.007
21. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001,411(6835):355-365. 10.1038/35077225
22. Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN: Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev 2012,26(11):1247-1262. 10.1101/gad.193565.112
23. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS: De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013,3(5):534-547. 10.1158/2159-8290.CD-12-0502
24. Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, Maira G, Pollo B, Mangiola A, DiMeco F, Dalprà L, Vescovi AL: Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 2009,28(15):1807-1811. 10.1038/onc.2009.27
25. Mangiola A, Saulnier N, De Bonis P, Orteschi D, Sica G, Lama G, Pettorini BL, Sabatino G, Zollino M, Lauriola L, Colabianchi A, Proietti G, Kovacs G, Maira G, Anile C: Gene expression profile of Glioblastoma peritumoral tissue: an ex vivo study. PLoS One 2013,8(3):e57145. 10.1371/journal.pone.0057145
26. Fortini ME: Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009, 19:633-647.
27. Wall DS, Mears AJ, McNeill B, Mazerolle C, Thurig S, Wang Y, Kageyama R, Wallace VA: Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic hedgehog/Hes1 activity. J Cell Biol 2009,184(1):101-112. 10.1083/jcb.200805155
28. Chen J, Huang Q, Wang F: Inhibition of FoxO1 nuclear exclusion prevents metastasis of Glioblastoma. Tumour Biol 2014. Apr 27. (Epub ahead of print)
29. Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, Qiu Y, Xie Q, Ge J: Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. Cancer Sci 2012,103(2):181-190. 10.1111/j.1349-7006.2011.02154.x
30. Vivanco I, Mellinghoff IK: Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 2010,22(6):573-578. 10.1097/CCO.0b013e32833edbdf
31. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH: Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010,98(1):93-99. 10.1007/s11060-009-0067-2
32. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 1, 5:67. 10.1186/1476-4598-5-67
33. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG: NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010,28(1):5-16.
34. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R: Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012,30(19):2307-2313. 10.1200/JCO.2011.39.1540
35. Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussiere M, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A: Prevalence, clinico-pathological value, and cooccurrence of PDGFRA abnormalities in diffuse gliomas. Neuro Oncol 2012,14(11):1393-1403. 10.1093/neuonc/nos217
36. Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, Gotoh Y: Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat Cell Biol 2004,6(6):547-554. 10.1038/ncb1138
37. Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 2013,288(36):26167-26176. 10.1074/jbc.M113.477950
38. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, DingL GT, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, et al.: Cancer Genome Atlas Research Network: integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010,17(1):98-110. 10.1016/j.ccr.2009.12.020
39. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, Su Q, Kotliarov Y, Lee J, Zhang W, Fine HA: Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 2008,29(5):918-925. 10.1093/carcin/bgn079
40. Xu P, Qiu M, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, Jiang H, Pu P: The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo. J Neurooncol 2010,97(1):41-51. 10.1007/s11060-009-0007-1
41. Ghosh MK, Sharma P, Harbor PC, Rahaman SO, Haque SJ: PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells. Oncogene 2005,24(49):7290-7300. 10.1038/sj.onc.1208894
42. Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C, Zhang J: IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 2010,100(2):165-176. 10.1007/s11060-010-0158-0
43. Uhrbom L, Hesselager G, Nister M, Westermark B: Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998, 58:5275-5279.
44. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 1, 86:131-140. 10.1172/JCI114675
45. Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-b is induced during tumor development and upregulated during tumor progression in endothe- lial cells in human gliomas. Lab Invest 1992, 67:529-534.
46. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, Depinho RA, Cavenee WK: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 1, 21:2683-2710. 10.1101/gad.1596707
47. Feng H, Liu KW, Guo P, Zhang P, Cheng T, McNiven MA, Johnson GR, Hu B, Cheng SY: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion. Oncogene 2012,31(21):2691-2702. 10.1038/onc.2011.436
48. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW: Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 2012,109(8):3041-3046. 10.1073/pnas.1114033109
49. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007,318(5848):287-290. 10.1126/science.1142946
50. Lama G, Angelucci C, Recchia F, Sica G: Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Cancer Lett 1996,100(1-2):181-189. Erratum in: Cancer Lett 1996, 103 (2): 243